60
Participants
Start Date
September 21, 2023
Primary Completion Date
June 16, 2030
Study Completion Date
June 16, 2030
NXT007
Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
RECRUITING
Auckland Cancer Trial Centre, Auckland
WITHDRAWN
Georgetown Uni Medical Center, Washington D.C.
RECRUITING
Istituto Clinico Humanitas, Rozzano (MI)
RECRUITING
Hospital Universitario la Paz, Madrid
ACTIVE_NOT_RECRUITING
Hospital Regional Universitario Carlos Haya, Málaga
RECRUITING
Indiana Hemophilia & Thrombosis center, Indianapolis
RECRUITING
University of Iowa Hospitals and Clnics Dept of Pediatrics, Iowa City
RECRUITING
UC Davis Cancer Center, Sacramento
RECRUITING
British Columbia Children's Hospital, Vancouver
RECRUITING
Hamilton Health Sciences Corporation, Hamilton
RECRUITING
Uniwersyteckie Centrum Kliniczne, Gda?sk
RECRUITING
Instytut Hematologii i Transfuzjologii, Warsaw
Hoffmann-La Roche
INDUSTRY